Palatin Technologies, Inc. (PTN)
USD 0.23
(-7.85%)
USD 0.23
(-7.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 34.67 Million USD | -8.57% |
| 2023 | 37.92 Million USD | 0.22% |
| 2022 | 37.83 Million USD | 25.03% |
| 2021 | 30.26 Million USD | 27.56% |
| 2020 | 23.72 Million USD | -3.39% |
| 2019 | 24.55 Million USD | -40.41% |
| 2018 | 41.2 Million USD | -25.47% |
| 2017 | 55.29 Million USD | 12.27% |
| 2016 | 49.25 Million USD | 62.88% |
| 2015 | 30.23 Million USD | 91.53% |
| 2014 | 15.78 Million USD | 1.23% |
| 2013 | 15.59 Million USD | -17.31% |
| 2012 | 18.85 Million USD | 24.66% |
| 2011 | 15.12 Million USD | -12.02% |
| 2010 | 17.19 Million USD | -7.82% |
| 2009 | 18.65 Million USD | -33.65% |
| 2008 | 28.11 Million USD | -36.4% |
| 2007 | 44.2 Million USD | -7.63% |
| 2006 | 47.85 Million USD | 47.23% |
| 2005 | 32.5 Million USD | 11.81% |
| 2004 | 29.07 Million USD | 30.34% |
| 2003 | 22.3 Million USD | 30.28% |
| 2002 | 17.12 Million USD | 30.36% |
| 2001 | 13.13 Million USD | -5.81% |
| 2000 | 13.94 Million USD | -1.8% |
| 1999 | 14.2 Million USD | 18.33% |
| 1998 | 12 Million USD | 87.5% |
| 1997 | 6.4 Million USD | 126.15% |
| 1996 | 2.83 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 8.21 Million USD | -28.25% |
| 2024 Q4 | 8.67 Million USD | -5.72% |
| 2024 Q3 | 9.02 Million USD | 7.19% |
| 2024 Q2 | 8.41 Million USD | 2.46% |
| 2023 FY | 37.92 Million USD | 0.22% |
| 2023 Q3 | 8.36 Million USD | 10.95% |
| 2023 Q2 | 7.54 Million USD | -20.91% |
| 2023 Q1 | 9.53 Million USD | -30.82% |
| 2023 Q4 | 11.44 Million USD | 36.82% |
| 2022 FY | 37.83 Million USD | 25.03% |
| 2022 Q1 | 7.32 Million USD | -22.38% |
| 2022 Q2 | 8.74 Million USD | 19.43% |
| 2022 Q3 | 7.98 Million USD | -8.63% |
| 2022 Q4 | 13.78 Million USD | 72.53% |
| 2021 Q1 | 5.25 Million USD | -28.88% |
| 2021 FY | 30.26 Million USD | 27.56% |
| 2021 Q2 | 9.05 Million USD | 72.32% |
| 2021 Q3 | 6.51 Million USD | -28.01% |
| 2021 Q4 | 9.43 Million USD | 44.67% |
| 2020 Q3 | 5.71 Million USD | 0.91% |
| 2020 Q1 | 4.95 Million USD | -38.61% |
| 2020 Q2 | 5.66 Million USD | 14.15% |
| 2020 Q4 | 7.38 Million USD | 29.34% |
| 2020 FY | 23.72 Million USD | -3.39% |
| 2019 Q2 | 5.05 Million USD | -10.83% |
| 2019 Q1 | 5.66 Million USD | -32.17% |
| 2019 Q3 | 5.76 Million USD | 14.11% |
| 2019 Q4 | 8.07 Million USD | 40.21% |
| 2019 FY | 24.55 Million USD | -40.41% |
| 2018 Q2 | 7.67 Million USD | -51.16% |
| 2018 Q1 | 15.7 Million USD | -19.78% |
| 2018 FY | 41.2 Million USD | -25.47% |
| 2018 Q3 | 9.48 Million USD | 23.58% |
| 2018 Q4 | 8.34 Million USD | -11.93% |
| 2017 Q3 | 13.83 Million USD | 46.55% |
| 2017 Q4 | 19.58 Million USD | 41.52% |
| 2017 FY | 55.29 Million USD | 12.27% |
| 2017 Q2 | 9.44 Million USD | -24.08% |
| 2017 Q1 | 12.43 Million USD | -2.38% |
| 2016 Q3 | 12.08 Million USD | -4.3% |
| 2016 Q4 | 12.73 Million USD | 5.4% |
| 2016 FY | 49.25 Million USD | 62.88% |
| 2016 Q2 | 12.62 Million USD | 7.04% |
| 2016 Q1 | 11.79 Million USD | 0.15% |
| 2015 Q4 | 11.78 Million USD | 35.06% |
| 2015 Q2 | 5.69 Million USD | 41.06% |
| 2015 FY | 30.23 Million USD | 91.53% |
| 2015 Q3 | 8.72 Million USD | 53.11% |
| 2015 Q1 | 4.03 Million USD | -6.54% |
| 2014 Q3 | 3.36 Million USD | -6.83% |
| 2014 Q2 | 3.61 Million USD | -19.64% |
| 2014 Q1 | 4.49 Million USD | -4.82% |
| 2014 FY | 15.78 Million USD | 1.23% |
| 2014 Q4 | 4.32 Million USD | 28.45% |
| 2013 Q3 | 4.02 Million USD | 16.72% |
| 2013 Q4 | 4.72 Million USD | 17.31% |
| 2013 FY | 15.59 Million USD | -17.31% |
| 2013 Q1 | 3.4 Million USD | -40.3% |
| 2013 Q2 | 3.44 Million USD | 1.26% |
| 2012 FY | 18.85 Million USD | 24.66% |
| 2012 Q4 | 5.7 Million USD | -5.76% |
| 2012 Q3 | 6.05 Million USD | 62.96% |
| 2012 Q2 | 3.71 Million USD | 9.4% |
| 2012 Q1 | 3.39 Million USD | -28.44% |
| 2011 FY | 15.12 Million USD | -12.02% |
| 2011 Q4 | 4.74 Million USD | 77.09% |
| 2011 Q3 | 2.67 Million USD | -6.82% |
| 2011 Q2 | 2.87 Million USD | -40.55% |
| 2011 Q1 | 4.83 Million USD | -1.91% |
| 2010 Q4 | 4.92 Million USD | 7.26% |
| 2010 Q2 | 3.84 Million USD | 0.64% |
| 2010 Q1 | 3.82 Million USD | -14.29% |
| 2010 FY | 17.19 Million USD | -7.82% |
| 2010 Q3 | 4.59 Million USD | 19.42% |
| 2009 FY | 18.65 Million USD | -33.65% |
| 2009 Q2 | 3.99 Million USD | -21.97% |
| 2009 Q3 | 5.08 Million USD | 27.47% |
| 2009 Q4 | 4.46 Million USD | -12.32% |
| 2009 Q1 | 5.11 Million USD | -19.47% |
| 2008 FY | 28.11 Million USD | -36.4% |
| 2008 Q1 | 9.6 Million USD | 5.0% |
| 2008 Q2 | 6.12 Million USD | -36.27% |
| 2008 Q3 | 6.04 Million USD | -1.29% |
| 2008 Q4 | 6.35 Million USD | 5.14% |
| 2007 Q1 | 13.68 Million USD | 3.72% |
| 2007 FY | 44.2 Million USD | -7.63% |
| 2007 Q3 | 10.15 Million USD | -9.57% |
| 2007 Q2 | 11.22 Million USD | -17.99% |
| 2007 Q4 | 9.14 Million USD | -9.9% |
| 2006 FY | 47.85 Million USD | 47.23% |
| 2006 Q2 | 10.86 Million USD | -3.84% |
| 2006 Q4 | 13.19 Million USD | 3.15% |
| 2006 Q3 | 12.79 Million USD | 17.73% |
| 2006 Q1 | 11.3 Million USD | 6.73% |
| 2005 Q1 | 7.55 Million USD | 8.76% |
| 2005 Q2 | 7.62 Million USD | 0.92% |
| 2005 Q3 | 6.81 Million USD | -10.62% |
| 2005 FY | 32.5 Million USD | 11.81% |
| 2005 Q4 | 10.58 Million USD | 55.42% |
| 2004 FY | 29.07 Million USD | 30.34% |
| 2004 Q2 | 5.2 Million USD | -39.73% |
| 2004 Q3 | 8.29 Million USD | 59.37% |
| 2004 Q4 | 6.94 Million USD | -16.25% |
| 2004 Q1 | 8.63 Million USD | 30.05% |
| 2003 Q2 | 4.87 Million USD | 2.24% |
| 2003 Q4 | 6.63 Million USD | 10.18% |
| 2003 Q3 | 6.02 Million USD | 23.59% |
| 2003 Q1 | 4.76 Million USD | -8.17% |
| 2003 FY | 22.3 Million USD | 30.28% |
| 2002 Q3 | 4.66 Million USD | 14.95% |
| 2002 FY | 17.12 Million USD | 30.36% |
| 2002 Q1 | 2.79 Million USD | -23.21% |
| 2002 Q2 | 4.05 Million USD | 45.3% |
| 2002 Q4 | 5.19 Million USD | 11.39% |
| 2001 FY | 13.13 Million USD | -5.81% |
| 2001 Q4 | 3.63 Million USD | 21.42% |
| 2001 Q3 | 2.99 Million USD | -8.59% |
| 2001 Q2 | 3.27 Million USD | 1.34% |
| 2001 Q1 | 3.23 Million USD | 47.54% |
| 2000 Q4 | 2.19 Million USD | -36.03% |
| 2000 Q2 | 5 Million USD | 51.52% |
| 2000 Q3 | 3.42 Million USD | -31.52% |
| 2000 Q1 | 3.3 Million USD | -29.79% |
| 2000 FY | 13.94 Million USD | -1.8% |
| 1999 Q4 | 4.7 Million USD | 46.88% |
| 1999 Q1 | 3.3 Million USD | -19.51% |
| 1999 Q2 | 3 Million USD | -9.09% |
| 1999 FY | 14.2 Million USD | 18.33% |
| 1999 Q3 | 3.2 Million USD | 6.67% |
| 1998 Q1 | 2.3 Million USD | 20.42% |
| 1998 FY | 12 Million USD | 87.5% |
| 1998 Q4 | 4.1 Million USD | 20.59% |
| 1998 Q2 | 2.3 Million USD | 0.0% |
| 1998 Q3 | 3.4 Million USD | 47.83% |
| 1997 Q4 | 1.91 Million USD | 3.8% |
| 1997 Q1 | 1.14 Million USD | 0.0% |
| 1997 FY | 6.4 Million USD | 126.15% |
| 1997 Q3 | 1.84 Million USD | 75.24% |
| 1997 Q2 | 1.05 Million USD | -7.89% |
| 1996 FY | 2.83 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | -8.088% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -274.087% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -197.626% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 33.327% |
| Azitra, Inc. | 8.3 Million USD | -317.595% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -287.899% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -405.231% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -19.586% |
| CEL-SCI Corporation | 31.47 Million USD | -10.148% |
| iBio, Inc. | 16.85 Million USD | -105.649% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | -5.04% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -71.786% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -39.451% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -148.862% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -168.805% |
| NanoViricides, Inc. | 8.51 Million USD | -307.116% |
| Oragenics, Inc. | 5.45 Million USD | -535.927% |
| BiomX Inc. | 26.81 Million USD | -29.3% |
| BiomX Inc. | 26.81 Million USD | -29.3% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | -8.169% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 12.923% |
| Theriva Biologics, Inc. | 21.43 Million USD | -61.777% |